What is MaxCyte?
MaxCyte operates as a clinical-stage global leader in cell-based therapies and life sciences. The company is defined by its proprietary cell engineering platform, which serves as a foundational technology for developing next-generation medical treatments. By enabling precise manipulation of cells, MaxCyte provides the essential tools required for researchers and pharmaceutical partners to translate complex scientific discoveries into viable clinical applications. Its market position is bolstered by a robust intellectual property portfolio and a proven track record of supporting high-impact therapeutic development, effectively bridging the gap between laboratory innovation and patient-centric care.
How much funding has MaxCyte raised?
MaxCyte has raised a total of $77.3M across 6 funding rounds:
Series A
$8M
Series B
$10.7M
Stock Offering
$14.4M
Share Placement
$12.3M
Debt
$1M
Share Placement
$30.9M
Series A (2003): $8M with participation from Undisclosed
Series B (2004): $10.7M led by Intersouth Partners, Harbert Venture Partners, and Tall Oaks Capital
Stock Issuance/Offering (2016): $14.4M supported by Undisclosed
Share Placement (2019): $12.4M featuring Undisclosed
Debt (2020): $1M backed by PPP
Share Placement (2020): $30.9M with participation from Sofinnova Crossover and Casdin Capital
Key Investors in MaxCyte
Harbert Venture Partners
A private equity firm specializing in mezzanine, middle market, and later-stage investments across the technology and life sciences sectors in the US and Europe.
Tall Oaks Capital
An investment firm focused on seed and early-stage opportunities, prioritizing companies with defensible intellectual property and significant market innovation.
Casdin Capital
A specialized investment firm with deep expertise in life science innovation, focusing on diagnostics, molecular information, and next-generation healthcare pioneers.
What's next for MaxCyte?
With the recent capital injection, MaxCyte is well-positioned to expand its operational footprint and accelerate the commercialization of its cell engineering solutions. The strategic focus will likely shift toward deepening its presence in the global cell therapy market, enhancing its R&D capabilities, and fostering new partnerships with biopharmaceutical entities. As the company moves through its current lifecycle stage, the emphasis remains on scaling its platform to meet the increasing demand for sophisticated, scalable, and efficient cell-based manufacturing processes. This strategic roadmap is designed to sustain long-term growth while maintaining the company's commitment to delivering transformative medical outcomes.
See full MaxCyte company page
